Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human liver-associated lymphocytes: an overview

M Winnock1, M Garcia Barcina, B Lukomska

  • 1Laboratoire des Interactions Cellulaires, Université de Bordeaux II, France.

Journal of Gastroenterology and Hepatology
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SOD1/Rag2 Mice with Low Copy Number of SOD1 Gene as a New Long-Living Immunodeficient Model of ALS.

Scientific reports·2019
Same author

Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort].

HIV medicine·2016
Same author

To Pringle or not to pringle: is Pedicle clamping a necessity in liver resection?

Hepato-gastroenterology·2014
Same author

Interest of contrast-enhanced sonography to identify focal nodular hyperplasia with sinusoidal dilatation.

Diagnostic and interventional imaging·2013
Same author

Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.

HIV medicine·2013
Same author

Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions.

HIV medicine·2013
Same journal

Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open-Label Randomized Clinical Trial.

Journal of gastroenterology and hepatology·2026
Same journal

Antibiotic Resistance Heterogeneity as an Unmeasured Confounder in Tegoprazan-Amoxicillin Dual Therapy Meta-Analysis.

Journal of gastroenterology and hepatology·2026
Same journal

Optimal Timing of Resuming Anticoagulant After Colorectal Endoscopic Submucosal Dissection: A Critical Appraisal.

Journal of gastroenterology and hepatology·2026
Same journal

Comments on "Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial".

Journal of gastroenterology and hepatology·2026
Same journal

Comment on "Association of Proton Pump Inhibitor and Potassium-Competitive Acid Blocker Use With Discontinuation and Intolerance of Oral 5-Aminosalicylic Acid in Patients With Ulcerative Colitis".

Journal of gastroenterology and hepatology·2026
Same journal

Response to Dileep et al. Regarding the J-GESS Score.

Journal of gastroenterology and hepatology·2026
See all related articles

Liver-associated lymphocytes (LAL) are a distinct cell type in liver sinusoids, differing phenotypically and functionally from peripheral blood lymphocytes (PBL). LAL exhibit unique immune markers and activity, suggesting site-specific roles in liver immunity.

Area of Science:

  • Immunology
  • Cell Biology
  • Hepatology

Background:

  • Liver sinusoids host a heterogeneous lymphocyte population beyond large granular lymphocytes.
  • Existing data suggest these cells, termed liver-associated lymphocytes (LAL), represent a unique sinusoidal cell type.

Purpose of the Study:

  • To characterize the phenotype and function of liver-associated lymphocytes (LAL).
  • To compare LAL with peripheral blood lymphocytes (PBL) to identify site-specific immune cell characteristics.
  • To investigate the impact of liver pathology on LAL phenotype and function.

Main Methods:

  • Flow cytometry analysis of isolated human LAL and PBL.
  • Phenotypic characterization using cell surface markers (CD56, CD8, CD4, CD3, CD16).
  • Assessment of Natural Killer (NK) and Lymphokine-Activated Killer (LAK) cell activity.

Related Experiment Videos

Main Results:

  • LAL display a distinct phenotype compared to PBL, with increased CD56+ and CD8+ cells and decreased CD4+ cells.
  • LAL exhibit higher NK cell activity than PBL.
  • LAL possess LAK activity, which is significantly reduced in patients with liver metastases, particularly in cells near tumors.

Conclusions:

  • Liver-associated lymphocytes (LAL) are a phenotypically and functionally distinct lymphocyte population within the liver sinusoids.
  • LAL possess unique immune surveillance capabilities, including NK and LAK activity.
  • Tumor cells may inhibit LAL cytotoxic functions, suggesting a role for LAL in anti-tumor immunity within the liver.